{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:54:48Z","timestamp":1793145288465,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"36","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["CA275990"],"award-info":[{"award-number":["CA275990"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["CA278889"],"award-info":[{"award-number":["CA278889"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["PC230358"],"award-info":[{"award-number":["PC230358"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["FP00016492"],"award-info":[{"award-number":["FP00016492"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR190021"],"award-info":[{"award-number":["RR190021"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint B7-H3 is an emerging target for immunotherapy. DS-7300a is an advanced B7-H3-targeting antibody-drug conjugate (ADC) warheaded with the topoisomerase I inhibitor DXd. DS-7300a has demonstrated clinical activity, but molecular biomarkers to predict its therapeutic response remain elusive.\n                    <jats:italic>TP53<\/jats:italic>\n                    is one of the most mutated tumor suppressor genes across cancers, and effective therapies are urgently needed for\n                    <jats:italic>TP53<\/jats:italic>\n                    -deficient cancers. Using prostate cancer (PCa) as a model system, we reported that DS-7300a\u2019s anti-tumor efficacy is highly dependent on functional p53 in cancer cells, and\n                    <jats:italic>TP53<\/jats:italic>\n                    defects confer resistance to DS-7300a. Mechanistically, we found that DS-7300a and its payload, DXd, induce DNA damage and activate the ATM\/ATR\/CHK signaling cascade, thereby stabilizing p53 and inducing a pro-apoptotic and senescence-associated transcriptome. In contrast,\n                    <jats:italic>TP53<\/jats:italic>\n                    -deficient cells fail to sense DXd-induced DNA damage, maintain a high proliferation rate, and exhibit low levels of apoptosis and senescence, thereby conferring resistance to DS-7300a. Ferroptosis is an iron-dependent form of regulated cell death triggered by lipid peroxidation, which is mechanistically and morphologically distinct from apoptosis. Interestingly, DS-7300a treatment elevates lipid peroxidation in TP53-deficient cancer cells and upregulates glutathione peroxidase 4 (GPX4), an antioxidant enzyme that mitigates lipid peroxidation. Using isogeneic xenograft models and a newly developed humanized B7-H3 PCa model, we demonstrated that inducing ferroptosis by pharmacological inhibition of GPX4 enhances DS-7300a\u2019s efficacy in\n                    <jats:italic>TP53<\/jats:italic>\n                    -deficient tumors. Our studies demonstrate that TP53 status dictates anti-tumor responses to DS-7300a, and ferroptosis induction represents a promising therapeutic approach to overcome resistance to DS-7300a in malignancies harboring TP53 defects.\n                  <\/jats:p>","DOI":"10.1038\/s41388-026-03921-7","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:37:59Z","timestamp":1785173879000},"page":"3753-3764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis"],"prefix":"10.1038","volume":"45","author":[{"given":"Javier","family":"Leo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenling","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaman","family":"Albittar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-6040","authenticated-orcid":false,"given":"Boyi","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3244-6096","authenticated-orcid":false,"given":"Kendra S.","family":"Carmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0713-471X","authenticated-orcid":false,"given":"Daniel E.","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-7127","authenticated-orcid":false,"given":"Di","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"3921_CR1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29:946\u201360.","journal-title":"Cell Death Differ"},{"key":"3921_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molmed.2006.07.007","volume":"12","author":"WP Roos","year":"2006","unstructured":"Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12:440\u201350.","journal-title":"Trends Mol Med"},{"key":"3921_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-cancerbio-050216-121926","volume":"1","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Lozano G. p53: multiple facets of a Rubik\u2019s cube. Annu Rev Cancer Biol. 2017;1:185\u2013201.","journal-title":"Annu Rev Cancer Biol"},{"key":"3921_CR4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;162:454.","journal-title":"Cell"},{"key":"3921_CR5","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3921_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research N","year":"2015","unstructured":"Cancer Genome Atlas Research NThe molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011\u201325.","journal-title":"Cell"},{"key":"3921_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239\u201343.","journal-title":"Nature"},{"key":"3921_CR8","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","volume":"22","author":"AM Aparicio","year":"2016","unstructured":"Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016;22:1520\u201330.","journal-title":"Clin Cancer Res"},{"key":"3921_CR9","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3921_CR10","first-page":"232","volume":"22","author":"C Huggins","year":"1972","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232\u201340.","journal-title":"CA Cancer J Clin"},{"key":"3921_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"3921_CR12","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","volume":"30","author":"AT Lenis","year":"2024","unstructured":"Lenis AT, Ravichandran V, Brown S, Alam SM, Katims A, Truong H, et al. Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer. Clin Cancer Res. 2024;30:3894\u2013903.","journal-title":"Clin Cancer Res"},{"key":"3921_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315\u201337.","journal-title":"Nat Rev Drug Discov"},{"key":"3921_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","volume":"6","author":"Y Pommier","year":"2006","unstructured":"Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6:789\u2013802.","journal-title":"Nat Rev Cancer"},{"key":"3921_CR15","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097\u2013108.","journal-title":"Clin Cancer Res"},{"key":"3921_CR16","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.bmcl.2016.02.020","volume":"26","author":"T Nakada","year":"2016","unstructured":"Nakada T, Masuda T, Naito H, Yoshida M, Ashida S, Morita K, et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett. 2016;26:1542\u20135.","journal-title":"Bioorg Med Chem Lett"},{"key":"3921_CR17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1158\/1535-7163.MCT-21-0554","volume":"21","author":"M Yamato","year":"2022","unstructured":"Yamato M, Hasegawa J, Maejima T, Hattori C, Kumagai K, Watanabe A, et al. DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody-drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models. Mol Cancer Ther. 2022;21:635\u201346.","journal-title":"Mol Cancer Ther"},{"key":"3921_CR18","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1158\/2159-8290.CD-20-1434","volume":"11","author":"K Iida","year":"2021","unstructured":"Iida K, Abdelhamid Ahmed AH, Nagatsuma AK, Shibutani T, Yasuda S, Kitamura M, et al. Identification and therapeutic targeting of GPR20, selectively expressed in gastrointestinal stromal tumors, with DS-6157a, a first-in-class antibody-drug conjugate. Cancer Discov. 2021;11:1508\u201323.","journal-title":"Cancer Discov"},{"key":"3921_CR19","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329\u201340.","journal-title":"Mol Cancer Ther"},{"key":"3921_CR20","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512\u201322.","journal-title":"Lancet Oncol"},{"key":"3921_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382:610\u201321.","journal-title":"N Engl J Med"},{"key":"3921_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","volume":"22","author":"S Siena","year":"2021","unstructured":"Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22:779\u201389.","journal-title":"Lancet Oncol"},{"key":"3921_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/pcan.2016.49","volume":"20","author":"B Benzon","year":"2017","unstructured":"Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis. 2017;20:28\u201335.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3921_CR24","doi-asserted-by":"publisher","first-page":"19458","DOI":"10.1073\/pnas.0709802104","volume":"104","author":"X Zang","year":"2007","unstructured":"Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104:19458\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3921_CR25","doi-asserted-by":"publisher","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","volume":"67","author":"TJ Roth","year":"2007","unstructured":"Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67:7893\u20137900.","journal-title":"Cancer Res"},{"key":"3921_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21615-4","volume":"12","author":"L Brady","year":"2021","unstructured":"Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021;12:1426.","journal-title":"Nat Commun"},{"key":"3921_CR27","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/SLA.0b013e3181f1939d","volume":"252","author":"T Arigami","year":"2010","unstructured":"Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg. 2010;252:1044\u201351.","journal-title":"Ann Surg"},{"key":"3921_CR28","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.18632\/oncotarget.3097","volume":"6","author":"Y Mao","year":"2015","unstructured":"Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, et al. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015;6:3452\u201361.","journal-title":"Oncotarget"},{"key":"3921_CR29","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1158\/1078-0432.CCR-17-2852","volume":"24","author":"K Yonesaka","year":"2018","unstructured":"Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, et al. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. Clin Cancer Res. 2018;24:2653\u201364.","journal-title":"Clin Cancer Res"},{"key":"3921_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/ni967","volume":"4","author":"WK Suh","year":"2003","unstructured":"Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4:899\u2013906.","journal-title":"Nat Immunol"},{"key":"3921_CR31","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","volume":"22","author":"E Picarda","year":"2016","unstructured":"Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) fOR HUMAN CANCER IMMUnotherapy. Clin Cancer Res. 2016;22:3425\u201331.","journal-title":"Clin Cancer Res"},{"key":"3921_CR32","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","volume":"18","author":"D Loo","year":"2012","unstructured":"Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012;18:3834\u201345.","journal-title":"Clin Cancer Res"},{"key":"3921_CR33","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1158\/1078-0432.CCR-20-4221","volume":"27","author":"NM Kendsersky","year":"2021","unstructured":"Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, et al. The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models. Clin Cancer Res. 2021;27:2938\u201346.","journal-title":"Clin Cancer Res"},{"key":"3921_CR34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","volume":"31","author":"S Seaman","year":"2017","unstructured":"Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, et al. Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell. 2017;31:501\u2013515 e508.","journal-title":"Cancer Cell"},{"key":"3921_CR35","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","volume":"26","author":"J Theruvath","year":"2020","unstructured":"Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S, et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors. Nat Med. 2020;26:712\u20139.","journal-title":"Nat Med"},{"key":"3921_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","volume":"35","author":"H Du","year":"2019","unstructured":"Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35:221\u2013237 e228.","journal-title":"Cancer Cell"},{"key":"3921_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6724","volume":"15","author":"W Shi","year":"2023","unstructured":"Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, et al. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med. 2023;15:eadf6724.","journal-title":"Sci Transl Med"},{"key":"3921_CR38","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/S0959-8049(20)31102-3","volume":"138","author":"M Yamato","year":"2020","unstructured":"Yamato M, Hasegawa J, Hattori C, Maejima T, Shibutani T, Deguchi T, et al. DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, exhibits potent anti-tumor effects in nonclinical models. Eur J Cancer. 2020;138:S14\u2013S15.","journal-title":"Eur J Cancer"},{"key":"3921_CR39","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","volume":"25","author":"A Thomas","year":"2019","unstructured":"Thomas A, Pommier Y. Targeting topoisomerase I in the era of precision medicine. Clin Cancer Res. 2019;25:6581\u20139.","journal-title":"Clin Cancer Res"},{"key":"3921_CR40","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1126\/science.281.5383.1674","volume":"281","author":"S Banin","year":"1998","unstructured":"Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281:1674\u20137.","journal-title":"Science"},{"key":"3921_CR41","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1126\/science.281.5383.1677","volume":"281","author":"CE Canman","year":"1998","unstructured":"Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998;281:1677\u20139.","journal-title":"Science"},{"key":"3921_CR42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1101\/gad.14.3.289","volume":"14","author":"SY Shieh","year":"2000","unstructured":"Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000;14:289\u2013300.","journal-title":"Genes Dev"},{"key":"3921_CR43","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"3921_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22:381\u201396.","journal-title":"Nat Rev Cancer"},{"key":"3921_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cmet.2008.07.005","volume":"8","author":"A Seiler","year":"2008","unstructured":"Seiler A, Schneider M, Forster H, Roth S, Wirth EK, Culmsee C, et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12\/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 2008;8:237\u201348.","journal-title":"Cell Metab"},{"key":"3921_CR46","doi-asserted-by":"crossref","unstructured":"Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial. J Immunother Cancer. 2022;10:1\u201314.","DOI":"10.1136\/jitc-2021-004424"},{"key":"3921_CR47","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","volume":"29","author":"E Shenderov","year":"2023","unstructured":"Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med. 2023;29:888\u201397.","journal-title":"Nat Med"},{"key":"3921_CR48","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062\u201378.","journal-title":"Cell"},{"key":"3921_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05408-1","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13:974.","journal-title":"Cell Death Dis"},{"key":"3921_CR50","doi-asserted-by":"crossref","unstructured":"Tolmachev V, Vorobyeva A. Radionuclides in diagnostics and therapy of malignant tumors: new development. Cancers (Basel), 2022;14:1\u20135.","DOI":"10.3390\/cancers14020297"},{"key":"3921_CR51","doi-asserted-by":"crossref","unstructured":"Zhang S, Wang X, Gao X, Chen X, Li L, Li G, et al. Radiopharmaceuticals and their applications in medicine. Signal Transduct Target Ther. 2025;10:1\u201351.","DOI":"10.1038\/s41392-024-02041-6"},{"key":"3921_CR52","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3389\/fonc.2019.01398","volume":"9","author":"HH Zhou","year":"2019","unstructured":"Zhou HH, Chen X, Cai LY, Nan XW, Chen JH, Chen XX, et al. Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer. Front Oncol. 2019;9:1398.","journal-title":"Front Oncol"},{"key":"3921_CR53","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2016.07.035","volume":"381","author":"JL Roh","year":"2016","unstructured":"Roh JL, Kim EH, Jang HJ, Park JY, Shin D. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett. 2016;381:96\u2013103.","journal-title":"Cancer Lett"},{"key":"3921_CR54","first-page":"3001","volume":"17","author":"X Pan","year":"2019","unstructured":"Pan X, Lin Z, Jiang D, Yu Y, Yang D, Zhou H, et al. Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4-mediated ferroptosis. Oncol Lett. 2019;17:3001\u20138.","journal-title":"Oncol Lett"},{"key":"3921_CR55","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1038\/s41388-021-01790-w","volume":"40","author":"G Lei","year":"2021","unstructured":"Lei G, Zhang Y, Hong T, Zhang X, Liu X, Mao C, et al. Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene. 2021;40:3533\u201347.","journal-title":"Oncogene"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03921-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03921-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03921-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:02:43Z","timestamp":1788213763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03921-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":55,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2026,9,22]]}},"alternative-id":["3921"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03921-7","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}